These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 30198182)
1. Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration. Jelin E; Wisløff T; Moe MC; Heiberg T Acta Ophthalmol; 2018 Dec; 96(8):804-811. PubMed ID: 30198182 [TBL] [Abstract][Full Text] [Related]
2. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration. Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301 [TBL] [Abstract][Full Text] [Related]
6. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies. Lanzetta P; Cruess AF; Cohen SY; Slakter JS; Katz T; Sowade O; Zeitz O; Ahlers C; Mitchell P Acta Ophthalmol; 2018 Dec; 96(8):e911-e918. PubMed ID: 29659183 [TBL] [Abstract][Full Text] [Related]
7. Five-year outcomes of a personalized pro re nata treatment regimen with anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Stattin M; Forster J; Graf A; Ahmed D; Krebs I; Ansari-Shahrezaei S Acta Ophthalmol; 2019 Feb; 97(1):e131-e133. PubMed ID: 30281212 [No Abstract] [Full Text] [Related]
8. Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial. Feltgen N; Bertelmann T; Bretag M; Pfeiffer S; Hilgers R; Callizo J; Goldammer L; Bemme S; Hoerauf H Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):923-934. PubMed ID: 28102456 [TBL] [Abstract][Full Text] [Related]
9. Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. Kanadani TCM; Dos Reis Veloso CE; Dorairaj S; Nehemy MB Ophthalmic Res; 2017; 58(1):18-26. PubMed ID: 28301850 [TBL] [Abstract][Full Text] [Related]
10. Intraocular Vascular Endothelial Growth Factor Levels in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration. Hata M; Yamashiro K; Ooto S; Oishi A; Tamura H; Miyata M; Ueda-Arakawa N; Takahashi A; Tsujikawa A; Yoshimura N Invest Ophthalmol Vis Sci; 2017 Jan; 58(1):292-298. PubMed ID: 28114590 [TBL] [Abstract][Full Text] [Related]
11. REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Dolz-Marco R; Phasukkijwatana N; Sarraf D; Freund KB Retina; 2017 Feb; 37(2):222-233. PubMed ID: 27627752 [TBL] [Abstract][Full Text] [Related]
12. Bevacizumab dosing every 2 weeks for neovascular age-related macular degeneration refractory to monthly dosing. Mimouni M; Meshi A; Vainer I; Gershoni A; Koren T; Geffen N; Nemet AY; Segal O Jpn J Ophthalmol; 2018 Nov; 62(6):652-658. PubMed ID: 30269186 [TBL] [Abstract][Full Text] [Related]
13. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics. Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560 [TBL] [Abstract][Full Text] [Related]
15. SEMIAUTOMATED QUANTITATIVE APPROACH TO CHARACTERIZE TREATMENT RESPONSE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Real-World Study. Roberts PK; Nesper PL; Gill MK; Fawzi AA Retina; 2017 Aug; 37(8):1492-1498. PubMed ID: 27997513 [TBL] [Abstract][Full Text] [Related]
16. Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study. Silva R; Berta A; Larsen M; Macfadden W; Feller C; Monés J; Ophthalmology; 2018 Jan; 125(1):57-65. PubMed ID: 28893454 [TBL] [Abstract][Full Text] [Related]
17. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) in a Norwegian population of patients with neovascular age-related macular degeneration compared to a control population. Jelin E; Wisløff T; Moe MC; Heiberg T Health Qual Life Outcomes; 2019 Aug; 17(1):140. PubMed ID: 31412873 [TBL] [Abstract][Full Text] [Related]
18. Bilateral Neovascular Age-Related Macular Degeneration: Comparisons between First and Second Eyes. Chew JK; Zhu M; Broadhead GK; Luo K; Hong T; Chang AA Ophthalmologica; 2017; 238(1-2):23-30. PubMed ID: 28395293 [TBL] [Abstract][Full Text] [Related]
19. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab. Mathew R; Richardson M; Sivaprasad S Am J Ophthalmol; 2013 Apr; 155(4):720-6, 726.e1. PubMed ID: 23317653 [TBL] [Abstract][Full Text] [Related]
20. Identifying Predictors of Anti-VEGF Treatment Response in Patients with Neovascular Age-Related Macular Degeneration through Discriminant and Principal Component Analysis. Holz FG; Tadayoni R; Beatty S; Berger AR; Cereda MG; Hykin P; Hoyng CB; Wittrup-Jensen K; Altemark A; Nilsson J; Kim K; Sivaprasad S Ophthalmic Res; 2017; 58(1):49-55. PubMed ID: 27832661 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]